The results in Table 1 showed that the conjugates 3 and 11 had no cytotoxicity, while
murrayafoline A exhibited activity against to three human cancer cell lines including Hep-G2,
RD and FL with IC50 values of 6.18, 9.04 and 8.91 µg/mL, respectively. The evaluation of
cytotoxicity of murrayafoline A and its derivatives also revealed that the amine group (NH) at
9-position could play important role in the cytotoxicity of murrayafoline A. Finally, although
the conjugates 3 and 11 did not show the activity as expected, but this is a good orientation in
the design and synthesis of other bioactive derivatives of this carbazole.
7 trang |
Chia sẻ: honghp95 | Lượt xem: 479 | Lượt tải: 0
Bạn đang xem nội dung tài liệu Synthesis and cytotoxic activity evaluation of novel derivatives of murrayafoline A - Le Duc Anh, để tải tài liệu về máy bạn click vào nút DOWNLOAD ở trên
Journal of Science and Technology 54 (2C) (2016) 502-508
SYNTHESIS AND CYTOTOXIC ACTIVITY EVALUATION OF
NOVEL DERIVATIVES OF MURRAYAFOLINE A
Le Duc Anh1, *, Nguyen Thi Hai Ly2, Truong Ngoc Hung3, Nguyen Thi Nga3,
Nguyen Manh Cuon 3, Le Mai Huong3, Lê Phong3, Luu Van Chinh3, *
1Chemistry-Materials Institute, Institute of Military Science and Technology
17 Hoang Sam, Cau Giay, Hanoi
2Tran Phu Gifted High School, 12 Tran Phu, Luong Khánh Thien, Ngo Quyen, Hai Phong
3Institute of Natural Products Chemistry, VAST, 18 Hoang Quoc Viet, Cau Giay, Hanoi
*Email: chinhluuvan@gmail.com
Received: 20 May 2016; Accepted for publication: 29 October 2016
ABSTRACT
Two new conjugates of murrayafoline A with zerumbone and artemisinin 3, 11 were
prepared by N-alkylation, in which, compound 3 was synthesized from two consecutive N-
alkylation reactions. Their cytotoxicity was evaluated on four human cancer cell lines Hep-G2,
LU, RD and Fl. The result showed that both compounds exhibited no activity against the tested
cell lines.
Keywords: murrayafoline A, N-alkylation, cytotoxicity, sesquiterpene, conjugate.
1. INTRODUCTION
A number of natural carbazole alkaloids were recognized to exhibit potential biological
activities such as antimicrobial [1, 2], anti-HIV [3], anticancer [4, 5, 6] activities. Among them,
several compounds were used as drugs for treatment of cancer [7]. Especially, murrayafoline A,
a well-known carbazole alkaloid is promising cytotoxic carbazole in the roots of G. stenocarpa
in Vietnam. This carbazole was reported to show significant growth suppression of the human
leukemia cell line HL-60 due to apoptosis mediated by the activation of the caspase-9/caspase-3
pathway [7] and prevent heart diseases [8]. Recently, some of the N-substituted derivatives were
synthesized and evaluated the anti-inflamamtory activity [9]. However, no reports on the
synthesis and biological evaluation of conjugates between murrayfoline A and other bioactive
compounds are available. In this respect, we report herein the synthesis and cytotoxicity
evaluation of two new conjugates of murrayafoline A and sesquiterpenes.
2. MATERIALS AND METHODS
All chemicals were purchased from Sigma-Aldrich (USA). Murrayafoline A was isolated
from rhizome of Glycosmis stenocarpa in Vietnam. Melting points were measured in open
capillary tubes on a Buchi 530 (Switzerland) melting point apparatus and were uncorrected.
NMR spectra were recorded on a Bruker Advance 500M using tetramethylsilane (TMS) as
Synthesis and cytotoxic activity evaluation of novel derivatives of murrayafoline A
503
internal standard. Mass spectra were recorded on a FTICR MS Varian and an Agilent 1200
Series LC-MSD 6310 Ion Trap LC/MS.
1.1. Synthesis of conjugate 3
2.1.1. Synthesis of 3-(1-methoxy-3-methyl-N-carbazolyl)propyl bromide 2
Compound 2 was synthesized from murrayafoline A according to the procedure as
described in reference [9].
2.1.2. Synthesis of azazerumbone 7,8
Synthesis of zerumbone oximes 5, 6
To a solution of zerumbone (0.3 g, 1.38 mmol) in absolute ethanol (10 mL),
hydroxylamine hydrochloride (0.92 g, 13.8 mmol) and K2CO3 (0.96 g, 13.8 mmol) were added
at room temperature. The mixture was stirred for overnight and the solid was filtered off and
washed with ethanol. The filtrate was concentrated under reduced pressure to afford a white
solid mass, which was dissolved in dichloromethane (10 ml). The organic layer was washed
with water (3 × 10 mL) and dried over anhydrous sodium sulfate, the solvent was removed by
rotary evaporation to give a mixture (0.25 g, 90% yield) of E- and Z- zerumbone as white solid
which was used for next step without purification
Synthesis of azazerrumbones 7, 8
To a solution of zerumbone oximes 5, 6 (1.5 g, 6.43 mmol) in dry acetonitrile (20 mL),
anhydrous zinc chloride (0.17 g, 1.28 mmol) was added. The reaction mixture was reflux under
nitrogen streamline and the progress of the reaction was monitored on TLC using n-H:EtOAc
3:1. After completion of the reaction, solvent was removed under reduced pressure and the
residue was taken in dichloromethane (20 mL). The organic layer was washed with water (3 ×
20 mL), followed by brine (20 mL) and then dried over anhydrous sodium sulfate. The solvent
was evaporated to give crude product that was chromatographed on silica gel using n-hexane :
ethylacetate 3:1 to afford 7 (200 mg) and 8 (600 mg)
Azazerumbone 7: Yield 39.1 % (white crystals); mp: 145-147oC;ESI-MS (m/z):
234.1 [M + H]+;1H-NMR (500 MHz, DMSO-d6, ppm)δ 8.35 (s, 1H, H-1'), 6.13 (d, J = 15.5
Hz, 1H, H-4'), 5.81 (d, J = 15.5 Hz, 1H, H-3'), 5.05 (t, J = 7 Hz, 1H, H-11'), 4.72 (t, J = 7 Hz,
1H, H-7'), 2.24 (m, 2H, 2H-10'), 2.17 (m, 2H, 2H-9'), 2.12 (d, broad, J = 6.5 Hz, 2H, 2H-6'),
1.68 (s, 3H, H-13'), 1.52 (s, 3H, H-14'), 1.05 (s, 3H, H-15'), 1.05 (s, 3H, 3H-16'). 13C-NMR (125
MHz, DMSO-d6, ppm) δ 166.7 (C-2'), 147.5 (C-4'), 133.7 (C-8'), 130.8 (C-12'), 125.1 (C-11'),
124.4 (C-7'), 122.6 (C-3'), 39.0 (C-9'), 38.0 (C-6'), 36.2 (C-5'), 28.5 (C-15'), 28.5 (C-16'), 24.4
(C-10'), 16.7 (C-14'), 14.7 (C-13').
Azazerumbone 8: Yield 9.7 % (white crystals); mp: 165-167oC;ESI-MS (m/z): 234.3
[M + H]+;1H-NMR (500 MHz, DMSO-d6, ppm)δ 9.20 (d, J = 9.5 Hz, 1H, H-1'), 6.05 (d, d, J1 =
10 Hz, J2 = 14.5 Hz, 1H, H-12'), 5.37 (t, J = 6.5 Hz, 1H, H-4'), 5.13 (t, J = 6 Hz, 1H, H-8'), 4.68
(d, J = 14.5 Hz, 1H, H-7'), 2.29 (m, 2H, 2H-5'), 2.23 (t, J = 6.0 Hz, 2H, H-6'), 2.06 (d, J = 6.5
Hz, 2H, H-9'), 1.74 (s, 3H, 3H-13'), 1.52 (s, 3H, H-14'), 1.00 (s, 3H, H-15'), 1.00 (s, 3H, H-16').
13C-NMR (125 MHz, DMSO-d6, ppm) δ 172.0 (C-2'), 136.0 (C-4'), 133.2 (C-7'), 128.7 (C-3'),
127.6 (C-12'), 125.0 (C-8'), 117.3 (C-11'), 39.0 (C-6'), 38.1 (C-9'), 34.7 (C-10'), 32.2 (C-15'),
30.2 (C-16'), 24.1 (C-5'), 14.6 (C-14'), 13.1 (C-13').
Le Duc Anh, Nguyen Thi Hai Ly, Truong Ngoc Hung
504
2.1.3. Synthesis of conjugate 3
A mixture of 7 (233 mg, 1 mmol), K2CO3 (0.21 g, 1.5 mmol), compound 2 (0.42 g, 1.3
mmol) and (1-butyl)triethylammonium bromide (23.8 mg, 0.1 mmol) in dry
dimethylformamide (15 mL) was thoroughly stirred at room temperature for overnight and
solvent was removed under reduced pressure. The resulting mixture was dissolved in water (20
mL) and extracted with EtOAc (3 × 20 mL). The combined extract was dried over anhydrous
sodium sulfate and solvent was removed under reduced pressure. Crude 3 were purified by
column chromatography on silica gel eluting with n-hexane : ethylacetate.
Yield 53.6 % (White powder); mp: 130-132oC; 1H-NMR (500 MHz, DMSO-d6, ppm) δ
8.03 (d, J = 7.5 Hz, 1H, H-8), 7.50 (s, broad, 2H, H-4, H-5), 7.39 (t, J = 7.5 Hz, 1H, H-7), 7.13
(t, J = 7.5 Hz, 1H, H-6), 6.85 (s, 1H, H-2), 6.14 (d, J = 15.5 Hz, 1H, H-4), 5.79 (d, J = 15.5
Hz, 1H, H-3), 4.94 (m, 2H, H-7, H-11), 4.55 (m, 2H, 9-CH2-), 3.94 (s, 3H, 1-OCH3), 2.45
(s, 3H, 3-CH3), 2.14 (s, broad, 4H, 9-CH2-CH2-CH2-), 1.83-1.98 (s, broad, 6 H, H-10, H-6,
H-9), 1.68 (s, 3H, H-13), 1.53 (s, 6H, H-15, H-16). 13C-NMR (125 MHz, DMSO-d6,
ppm) δ 165.3 (C-2), 147.3 (C-4), 146.1 (C-1), 140.3 (C-13), 133.8 (C-8), 133.7 (C-12),
131.8 (C-11), 128.6 (C-3), 127.3 (C-10), 125.4 (C-7), 124.5 (C-7), 124.1 (C-12), 123.2 (C-
3), 122.2 (C-11), 120.1 (C-6), 118.6 (C-8), 112.5 (C-4), 109.2 (C-2, C-5), 55,7 (1-OCH3), 42,7
(9-CH2-), 40.6 (1-CH2-), 38.1 (C-9), 36.0 (C-5), 28.6 (9-CH2-CH2-), 25.0 (C-10), 21.3
(3-CH3), 15.0 (C-14), 14.7 (C-13). HR-MS (m/z): Found 485.31675 [M+H]+, calculated for
C32H41N2O2: 485.31625
2.2. Synthesis of conjugate 11
2.2.1. Synthesis of 2-(10β-dihydroartemisinoxy)ethyl bromide 10
The intermediate 10 was synthesized from dihydroarrtemisinin and 2-bromoethanol
according to the procedure as described in reference [10].
2.2.2. Synthesis of conjugate 11
A mixture of murrayafoline A (1) (0.211 g, 1 mmol), K2CO3 (0.621 g, 4.5 mmol),
compound 10 (1.25 g, 3 mmol) and (1-butyl)triethylammonium bromide (35.7 mg, 0.15 mmol)
in dry dimethylformamide (15 mL) was stirred at 70oC for 48 h and solvent was removed under
reduced pressure. The resulting mixture was dissolved in water (20 mL) and extracted with
EtOAc (3 × 20 mL). The combined extract was dried over anhydrous sodium sulfate and solvent
was removed under reduced pressure to afford crude 11 that was purified by column
chromatography on silica gel eluting with n-hexane : ethylacetate 2:1.
Yield 45.8 % (white crystals); mp: 176 – 178 oC; 1H-NMR (500 MHz, DMSO-d6, ppm) δ
7.99 (d, J = 7.5 Hz, 1H, H-8), 7.53 (d, J = 8 Hz, 1H, H-5), 7.49 (s, 1H, H-4), 7.37 (t, J = 8 Hz,
1H, H-7), 7.12 (t, J = 7.5 Hz, 1H, H-6), 6.85 (s, 1H, H-2), 4.80 (m, 1H, 9-CH2a-), 4.69 (m, 1H,
9-CH2b-) 4.59 (s, 1H, H-12), 4.54 (d, J = 3.5 Hz, 1H, H-10), 4.17 (m, 1H, 10-O-CH2a-),
3.96 (s, 3H, 1-OCH3), 3.64 (m, 1H, 10-O -CH2b-), 2.47 (s, 3H, 3-CH3), 2.22 (m, 1H, H-9),
2.08 (m, 1H, 4-CH2a-), 1.88 (m, 1H, 4-CH2b-), 1.66 (m, 1H, 5-CH2a-), 1.09 (m, 1H, 5-
CH2b-), 1.20 (s, 3H, 3-CH3), 1.15 (m, 1H, H-8a), 1.09 (m, 1H, 7-CH2a-), 0.59 (m, 1H, 7-
CH2b-), 1.03 (m, 1H, 8-CH2a-), 0.89 (m, 1H, 8-CH2b-), 0.89 (m, 1H, H-5a), 0.79 (d, J =
6Hz, 3H, 6-CH3), 0.59 (m, 1H, H-6) . 13C-NMR (125 MHz, DMSO-d6, ppm) δ 147.0 (C-1),
141.7 (C-8), 129.2 (C-3), 128.4 (C-10), 125.7 (C-7), 125.1 (C-12), 123.0 (C-11), 120.3 (C-6),
Synthesis and cytotoxic activity evaluation of novel derivatives of murrayafoline A
505
119.0 (C-8), 113.0 (C-4), 110.4 (C-2), 110.0 (C-5), 103.6 (C-3), 101.3 (C-10), 87.3 (C-
12), 80.8 (C-12a), 66.9 (10-O-CH2-), 56.4 ('-OCH3), 52.6 (C-5a), 44.9 (C-8a), 44.3 (9-
CH2-), 36.9 (C-6), 36.7 (C-4), 34.7 (C-7), 30.9 (C-9), 26.2 (C-15), 24.7 (C-5), 23.9
(C-8), 21.8 (3-CH3), 20.4 (C-14), 12.8 (C-13). HR-MS (m/z): 522.28550 [M+H]+,
calculated for C31H40NO6: 522.28502
2.3. In vitro anticancer assay
The in vitro evaluation of cytotoxicity was undertaken at Institute of Natural Products
Chemistry (VAST) according to the protocol of Likhitwitayawid [10]. The determination of
IC50 was carried out using four human cancer cell lines: HepG2, RD, LU-1 and FL with
ellipticine was used as a positive control. The IC50 values were determined from dose-dependent
curve plotted from five different concentration regimens (0 - 20 µM).
3. RESULT AND DISCUSSION
The aim of our synthesis was to introduce a murrayafoline A moiety connected to
sesquiterpenes, artemisinin and zerumbone by 1,3-propane or 1,2-ethane bridges to form the
conjugatates 3, 11 and evaluate their cytotoxicity. The synthesis of new conjugates 3 and 11 was
outlined in schemes 1, 2. For the synthesis of conjugates 3, on the one hand, 1-bromo-3-propyl
substituent was first introduced into the position N-9 of murrayafoline A by N-alkylation
reaction of 1 with 1,3-dibromopropane in THF in the presence of strong base NaH as catalyst to
give the key intermediate 2 in 83.0 % yield and by-product 3 in 10 % [10] (scheme 1). On the
other hand, azazerumbone 7 was also prepared from zerumbone by a procedure in two steps.
Firstly, zerumbone was condensed with hydroxylamine hydrochloride in ethanol with potasium
carbonate as catalyst to create zerumbone oximes 5 and 6 with E- and Z-configuration in 90 %
yield. In the next step, Beckmann rearrangement of 5 and 6 was conducted in the presence of
anhydrous zinc chloride in acetonitrile to afford azazerumbone 7 and 8 in 39.1 and 9.7 % yields,
respectively. The confirmed structures of 7 and 8 agreed with 1H-, 13C-NMR and MS data.
Finally, conjugate 3 was successfully synthesized in 53.6 % yield by N-alkylation of 7 with 2
using 10 % equivalent of transfer catalyst (1-butyl)triethylammonium bromide.
Scheme 1. Preparation of conjugate 3.
Reagents and conditions: (i) HO-NH2.HCl,EtOH, rt, 12 h, 90 %; (ii) ZnCl2, CH3CN, Reflux, 6 h, 39.1 %
and 9.7 %; (iii) 1,3-Dibromopropane, NaH, THF, 72 h, 83 % (2) and 11 % (2a); (iv) 2, K2CO3,
transfercatalyst 10 %, DMF, overnight, 53.6 %.
Le Duc Anh, Nguyen Thi Hai Ly, Truong Ngoc Hung
506
For the synthesis of conjugate 11, derivative 10 was prepared from dihydroartemisinin by
etherification with 2-bromoethanol using BF3.Et2O in CH2Cl2 to give intermediate 10 in 46 %
yield. This agent was used for N-alkylation of murrayafoline A in DMF in the presence of
transfer catalyst (1-butyl)triethylammonium bromide at 70oC for 48 h to obtain the target
compound 11 in 45.8 % yield (Scheme 2).
O
O
O
O
H
OH
O
O
O
O
H
O
Br
O
O
O
OH
ON
OCH3
9 10 11
i ii
2'
3' 4'
5'
6'
7'
8'9'
10'
11' 12'
13'
14'
15'
5'a
8'a
12'a
13
4
12
11
5
8
10
9
13
1'
Scheme 2. Preparation of conjugate 11.
Reagents and conditions: (i) 2-bromoethanol, BF3.Et2O, CH2Cl2, 0 oC–rt, 46 %;
(ii) Murrayafoline A,K2CO3, transfercatalyst 10 %, DMF, 70 oC,48h, 45.8 %.
1H-NMR spectra of 11 indicated the presence of two components murrayafoline A and
artemisinin. The aromatic protons of murrayafoline A appeared in the range with δ values from
6.90 – 8.11 ppm and the protons of artemisinin was found ranging from 0.53-4.92 ppm.
Especially, the signals of carbon at 83 and 102 ppm confirmed that endoperoxide bridge of
dihydroartemisinin was still preserved. The exact assignment for all protons and carbons in 11
was confirmed based on the HSQC and HMBC spectra. In HSQC spectrum, the correlation of
carbons 9-CH2- and 9-CH2-CH2- with their protons indicated the signals of protons in 9-CH2- at
1.11 and 2.22 ppm and in 9-CH2-CH2- at 333 and 444 ppm, respectively. The key cross peaks
between the protons of 9-CH2- with C-10 and C-13 of murrayafoline A were also found in
HMBC. The structure of conjugate 11 agreed well with NMR and MS spectra.
The evaluation of anti-proliferative activity of 3 and 11 was performed with the highest
concentration of compounds 3 and 11was used for the experiments was 20µg/mL. The IC50
values are listed in Table 1.
Table 1. The cytotoxic activity of 3 and 11.
No Compounds IC50 (μg/mL)a
Hep-G2b RDb LU-1b FLb
1 3 > > > >
2 11 > > > >
3 Murrayafoline A 6.18 9.04 - 8.91
4 Ellipticine 0.27 0.32 0.18 0.21
aIC50 shown for these compounds are the average of three determinations.
bCell lines: Hep-G2 (liver heptatocellular carcinoma, ATCC-HB-8065), LU (lung adenocarcinoma,
ACTT-HBT-57), RD (rhabdomyosarcoma, ATCC-CCL-136) and FL (HeLa derivative, human cervix
carcinoma).
Journal of Science and Technology 54 (2C) (2016) 502-508
507
The results in Table 1 showed that the conjugates 3 and 11 had no cytotoxicity, while
murrayafoline A exhibited activity against to three human cancer cell lines including Hep-G2,
RD and FL with IC50 values of 6.18, 9.04 and 8.91 µg/mL, respectively. The evaluation of
cytotoxicity of murrayafoline A and its derivatives also revealed that the amine group (NH) at
9-position could play important role in the cytotoxicity of murrayafoline A. Finally, although
the conjugates 3 and 11 did not show the activity as expected, but this is a good orientation in
the design and synthesis of other bioactive derivatives of this carbazole.
3. CONCLUSSION
Two new derivatives of murrayafoline A with zerumbone and artemisinin were
successfully synthesized in good yields and their structures were elucidated by spectroscopic
methods such as NMR and MS. The cytotoxic activity against the Hep-G2, LU, RD and FL of
the conjugates was assayed and the structure-antiproliferative activity relationship was also
discussed.
Ackowledgements. The authors are grateful to Vietnam Academy of Science and Technology (VAST) via
a project: VAST04.02/15-16.
REFERENCES
1. Cuong N. M., Wilhelm H., Porzel A., Arnold N., Wessjohann L. - 1-O-substituted
derivatives of murrayafoline A and their antifungal properties, Nat. Prod. Res. 22 950-
954 (2008).
2. Chakraborty B., Chakraborty S., Saha C. - Antibacterial activity of murrayaquinone A
and 6-methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione, Int. J.
Microbiology 2014 (2014) 1-8.
3. Meragelman K. M., McKee T. C., and Boyd M. R. - Siamenol, a new carbazole alkaloid
from Murraya siamensis, J. Nat. Prod. 63 (2000) 427-428.
4. Itoigawa M., Kashiwada Y., Ito C., Furukawa H., Tachibana Y., Bastow K. F., and Lee
K. H. - Antitumor agent. 203. Carbazole alkaloids murrayaquinone A and related
synthetic carbazolequinones as cytotoxic agents, J. Nat.Prod. 63 (2000) 893-897.
5. Fiebig M., Pezzuto J. M., Soejarto D. D., and Kinghorn A. D. - Koenoline, a further
cytotoxic carbazole alkaloid from Murraya koenigii, Phytochemistry 24 (1985) 3041-
3043
6. Chakrabarty M., Nath A. C., Khasnobis S., Chakrabarty M., Konda Y., Harigaya Y., and
Komiyama K. - Carbazole alkaloid from Murraya koenigii, Phytochemistry 46 (1997)
751-755.
7. Ito C., Itoigawa M., Nakao K., Murata T., Kaneda N., Furukawa H. - Apoptosis of HL 60
leukemia cells induced by carbazole alkaloids isolated from Murraya euchrestifolia, J.
Nat. Med. 66 (2012) 357–361.
8. Son M. J., Chidipi B., Kim J. C., Huong T. T., Tai B. H., Kim Y. H., Cuong N. M., Woo
S. H. - Alterations of contractions and L-type Ca2+ currents by murrayafoline A in rat
ventricular myocytes, Eur. J. of Pharmacol. 740 (2014) 81-87.
Le Duc Anh, Nguyen Thi Hai Ly, Truong Ngoc Hung
508
9. Thuy T. T. T., Cuong N. M., Toan T. Q., Thang N. N., Tai B. H., Nhiem N. X., Hong H.
J., Kim S. H., Legoupy S., Koh Y. S. - Synthesis of novel derivatives of murrayafoline A
and their inhibitory effect on LPS-stimulated production of proinflammatory cytokines in
bone marrow-derived dendritic cells, Archives of Pharmacal Research 36 (2013) 832-839.
10. Yajing L., Zijian L., Jiyue S., Huimin C., Bin M., Peng L. and Ping G. - Synthesis and
cytotoxicity of novel 10-substituted dihydroartemisinin derivatives containing N-
arylphenyl-ethenesulfonamide groups, Molecules 18 (2013) 2864-2877.
TÓM TẮT
TỔNG HỢP VÀ ĐÁNH GIÁ HOẠT TÍNH GÂYĐỘC TẾ BÀO CÁC DẪN XUẤT MỚI CỦA
MURRAYAFOLINE A
Lê Đức Anh1, *, Nguyễn Thị Hải Lý2, Trương Ngọc Hùng3, Nguyễn Thị Nga3,
Nguyễn Mạnh Cường3, Lê Mai Hương3, Lê Phong3, Lưu Văn Chính3, *
1Viện Hóa học Vật liệu, Viện Khoa học Công nghệ Quân sự, 17 Hoàng Sâm, Cầu Giấy, Hà Nội
2Trường Trung học phổ thông Chuyên Trần Phú, 12 Trần Phú, Ngô Quyền, Hải Phòng
3Viện Hóa học các hợp chất thiên nhiên, Viện Hàn lâm Khoa học và Công nghệ Việt Nam,
18 Hoàng Quốc Việt, Cầu Giấy, Hà Nội
*Email: chinhluuvan@gmail.com
Hai tổ hợp mới 3, 11 của murrayafoline A với zerumbone và artemisinin được chuẩn bị
bằng phản ứng N-ankyl hóa, trong đó hợp chất 3 được tổng hợp bằng 2 phản ứng N-alkyl hóa
liên tiếp. Hoạt tính gây độc tệ bào của chúng được đánh giá trên 4 dòng tế bào ung thư Hep-G2,
LU, RD và Fl. Kết quả chỉ ra rằng cả hai dẫn xuất đã không thể hiện hoạt tính với các dòng tế
bào được thử nghiệm.
Từ khóa: murrayafoline A, N-alkyl hóa, hoạt tính gây độc tế bào, sesquiterpen, tổ hợp.
Các file đính kèm theo tài liệu này:
- 11880_103810382199_1_sm_4117_2061520.pdf